Product Images Propofol

This is a description of the side effects of anesthesia and MAC sedation, including cardiovascular complications such as bradycardia, arrhythmia, tachycardia, and hypotension. Central nervous system reactions may include movement issues, while injection site reactions may include burning, stinging, or pain. Metabolic and respiratory side effects are also possible, such as hyperlipemia and apnea. Skin reactions, such as rash and pruritus, are possible as well. These side effects may be more common in pediatric patients.*

This document appears to be a graph showing the recovery time after different lengths of propofol infusions. The x-axis shows time in minutes after the end of the infusion and the y-axis shows target plasma concentration. However, without more context or information it is difficult to say for certain what this graph represents.*

This is a description of two tables featuring pediatric induction and maintenance of anesthesia. Table 1 shows the age range and median range of induction doses and injection durations for children from birth through 16 years. Table 2 displays maintenance dosage and duration ranges for children aged 2 months to 16 years, separated by age range. The information in the tables is intended to be a useful reference for administering anesthesia to pediatric patients.*

This is a medication regimen for inducing and maintaining anesthesia for medical procedures. The primary agent used for induction is Propofol Injectable Emulsion, with a preinduction rate of 25 mcg/kg/min for anxiolysis and an induction rate of 0.5-1.5 mg/kg over 60 seconds. The secondary agent used for maintenance is an opioid, titrated to clinical response between 0.05-0.075 mcg/kg/min without bolus. If the opioid is inadequate, Propofol Injectable Emulsion can be increased to 50-100 mcg/kg/min without bolus for maintenance with an initial induction rate of 25-50 mcg/kg. The maintenance rate for Propofol is 0.2-0.3 mcg/kg/min.*

This is a description of the concentration and packaging of medical product vials with specific NDC codes. The vials have different concentrations and quantities per unit of sale, with vials ranging from 200 mg/20mL to 1000mg/100mL in concentration. The vials are sold in cartons/trays containing 5-20 fliptop vials, and each vial has a 10mg/mL concentration.*

This is a description of the approved patient population for the initiation and maintenance of Monitored Anesthesia Care (MAQ) sedation, combined sedation, and regional anesthesia, induction and maintenance of General Anesthesia, and Intensive Care Unit (ICU) sedation of intubated, mechanically ventilated patients. This text specifies that these procedures are approved for adults only, and that there may be precautions for combined sedation and regional anesthesia for adults. The age requirements for patients are also specified for general anesthesia (≥3 years of age for induction, ≥2 months of age for maintenance).*

This is a medication that contains benzyl alcohol and is intended for intravenous administration. It is advised to shake well before using. The manufacturer is Hospira, Inc. located in Lake Forest, Illinois, USA.*

This is a product description for an injectable emulsion containing benzyl alcohol and Propofol. It is intended for intravenous administration and must be shaken before use. It has a concentration of 10mg/mL. The product is for single-patient use only, and the label includes a US patent number and NDC number. The rest of the text contains unclear characters and is not readable.*

This is a description of a single-use injectable emulsion with 500 mg/50 mL strength. The medicine contains propofol, soybean oil, glycerin, egg lecithin, benzylalcohol, and umbenzoate. Sodium is used to adjust its pH level, and it is manufactured in India. The product should be used with strict aseptic technique and must be shaken well before use. It should be stored safely and used only for a single patient.*